These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 12430884)

  • 1. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():176-83. PubMed ID: 12430850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical review on non-myeloablative stem cell transplantation (NST).
    Anagnostopoulos A; Giralt S
    Crit Rev Oncol Hematol; 2002 Nov; 44(2):175-90. PubMed ID: 12413634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-myeloablative stem cell transplant].
    Shoji N; Mineishi S
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):795-800. PubMed ID: 10897204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
    Shimoni A; Nagler A
    Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
    Handgretinger R; Kurtzberg J; Egeler RM
    Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplantation using non-myeloablative transplant regimens.
    Battiwalla M; Barrett J
    Best Pract Res Clin Haematol; 2001 Dec; 14(4):701-22. PubMed ID: 11924917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
    Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic haemopoietic stem cell transplantation using non-myeloablative conditioning--a local experience.
    Leong CF; Cheong SK; Fadilah SA; Ainoon O; Hamidah NH
    Med J Malaysia; 2003 Jun; 58(2):229-35. PubMed ID: 14569743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity allogeneic stem cell transplantation.
    Bearman SI
    Curr Hematol Rep; 2003 Jul; 2(4):277-86. PubMed ID: 12901324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies.
    Busca A; Bruno B; Boccadoro M; Locatelli F; Falda M
    Med Sci Monit; 2002 Oct; 8(10):RA221-32. PubMed ID: 12388932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.